Gilead Sciences, Inc.'s $1,000-A-Pill Hepatitis C Drug May Make Financial Sense For Prisons

Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.

Sovaldi's $1,000-a-pill price — or $84,000 for a 12-week course of treatments — has been criticized by pharmacy benefits manager Express Scripts (NASDAQ: ESRX) and others for potentially breaking private and public insurance programs. At the same time, leaders of Foster City-based Gilead (NASDAQ: GILD) have argued that Sovaldi actually saves money in the long term by preventing the use of liver cancer drugs and liver transplants.

Help employers find you! Check out all the jobs and post your resume.

Back to news